Cash, cash equivalents, restricted cash and short-term investments totaled $207.5 million as of September 30, 2025. The current cash position, without accounting for anticipated revenue from ZEVASKYN, is expected to be sufficient to fund current and planned operations for over two years.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics announces permanent J-Code for ZEVASKYN
- Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development
- Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA
- Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN